Clinical Trials

MainTitle

2-5 Intermittent Caloric Restriction for Weight Loss and Insulin Resistance in HIV-Infected Adults With Features of the Metabolic Syndrome

This study is currently recruiting participants. (see Contacts and Locations)

Verified January 29, 2020 by National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)


Information provided by (Responsible Party)
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier
NCT03489109

First received: April 4, 2018
Last updated: April 17, 2020
Last Verified: January 29, 2020
History of Changes
Purpose

Purpose

Background:

Weight gain can lead to obesity and diabetes even in people living with human immunodeficiency virus (HIV). Researchers want to see if the technique intermittent calorie restriction can help overweight people with HIV as an alternative to traditional diets.

Objective:

To see if intermittent calorie restriction leads to weight loss and improved blood sugar in obese people with HIV.

Eligibility:

Adults ages 18-65 with HIV who are obese and do not have diabetes

Design:

Participants will be screened with a medical history, physical exam, and blood and urine tests.

Before starting treatment, participants will:

  • Have a nutritional consultation
  • Get a pedometer to record daily steps
  • Test a restricted diet for 1 day
  • Have a body x-ray


  • At the baseline visit, participants will have:
  • Blood drawn after they drink a sugar drink
  • Questions about their health and eating
  • A nutritional consultation
  • Resting energy expenditure measured. Participants will fast overnight. Then they will lie down while a plastic bubble goes over the head and a plastic sheet covers the upper body. Oxygen flows into the bubble.
  • Liver stiffness test. A wand on the stomach releases sound waves like an ultrasound.
For 12 weeks, some participants will be on a standard diet. Others will restrict how much food they eat 2 days a week. On those days they will eat about 25% of their recommended calories.

Participants will keep a diary of their diet and steps.

Participants will have 4 visits during the 12-week diet and 1 visit 12 weeks after the diet ends. They will repeat previous tests.

Condition Intervention Phase
Human Immunodeficiency Virus
Metabolic Syndrome

Behavioral : Intermittent fasting
Other : Standard of Care
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: 2-5 Intermittent Caloric Restriction for Weight Loss and Insulin Resistance in HIV-Infected Adults With Features of the Metabolic Syndrome

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures

  • Change in weight and insulin sensitivity as measured by HOMA-IR [ Time Frame: Baseline, week 12, week 24 ]
    Weight
Secondary Outcome Measures:
  • Tolerability of ICR [ Time Frame: Baseline, Week 12, Week 24 ]
    Subject's tolerability to ICR and compliance as recorded on subject diary.
  • Change in lipid levels, metabolic biomarkers, biomarkers of inflammation and immune activation, and mood. [ Time Frame: Baseline, Week 12, Week 24 ]
    Change in lipids levels, metabolic biomarkers, biomarkers of inflammation and immune activation. Mood changes measured by subject questionnaires.
  • Change in body composition, including visceral adiposity abd hepatic steatosis. [ Time Frame: Baseline, Week 12, Week 24 ]
    Change in body composition, including visceral adiposity and hepatic steatosis measured by fibroscan.

Estimated Enrollment: 100
Study Start Date: May 9, 2018
Estimated Study Completion Date: January 31, 2022
Estimated Primary Completion Date: January 31, 2022 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Intermittent Fasting
Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet.
Behavioral: Intermittent fasting

Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet

Active Comparator: Standard of Care
Standard of care dietary and healthy lifestyle counseling
Other: Standard of Care

Subject will receive standard of care recommendations for healthy diet and lifestyle

Detailed Description:

The high prevalence of obesity coupled with chronic inflammation and immune activation places human immunodeficiency virus (HIV)-infected individuals at increased risk for metabolic complications emphasizing the need for more aggressive management of obesity and related co-morbidities in the aging HIV-infected population. The most effective treatment for obesity and metabolic syndrome is lifestyle modification, usually with a combination of caloric restriction and increased exercise. Intermittent caloric restriction (ICR) or intermittent fasting simplifies caloric restriction by severely limiting calories only a few days per week and allowing ad lib diet on the other days. Weight loss benefits are similar to those seen with conventional diets, however, data suggests possible added health benefits from intermittent fasting.
We propose to study the benefits of a 2-5 intermittent caloric restriction (ICR) strategy on weight, insulin resistance, and cardiovascular disease markers in obese HIV-infected adults with features of the metabolic syndrome. In a prospective pilot study, 50 HIVinfected adults will be randomized 1:1 to ICR or standard of care instruction of healthy diet and lifestyle for a 12-week intervention period. We hypothesize that ICR (2 days per week) will be an effective and acceptable diet strategy that will result in significant weight reduction, improvements in insulin sensitivity and related metabolic parameters.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 65 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

  • INCLUSION CRITERIA:
    1. Age 18 - 65 years
    2. HIV RNA level less than or equal to 200 copies/mL for greater than or equal to1 year (1 measure greater than or equal to 200 allowed if also <500 and preceded and followed by one or more undetectable values)
    3. CD4 > 200 cells/mL and no active opportunistic infection or malignancy
    4. BMI greater than or equal to 30 kg/m^2
    5. One or more components of the metabolic syndrome as defined below.
      • Risk Factor: Waist circumference
        • Men: Defining Level: > 102 cm
        • Women: Defining Level: > 88 cm
      • Risk Factor: Triglycerides, greater than or equal to 150 mg/dL
      • Risk Factor: High density lipoprotein (HDL) cholesterol
        • Men: Defining Level: < 40 mg/dL
        • Women: Defining Level: < 50 mg/dL
      • Risk Factor: Blood pressure, greater than or equal to 130 / greater than or equal to 85 mmHg
      • Risk Factor: Fasting glucose, greater than or equal to 110 mg/dL
    6. Fasting blood glucose > 60 mg/dL at screening
    7. Willingness to allow sample storage for future research


Exclusion Criteria:
  • Established diagnosis of diabetes mellitus use of anti-diabetes medications, or a HgbA1C of >7.0 %
  • History of eating disorder, uncontrolled mood or thought disorder, significant gastrointestinal disorder or malabsorption, or significant hepatic or renal impairment
  • Current use of medical therapy for overweight/obesity including phentermine, orlistat, lorcaserin, naltrexone/bupropion, and liraglutide or history of weight loss surgery. Concomitant use of medications with side effects known to potentially influence appetite are allowed if on a stable dose for at least 12 months
  • History of symptomatic hypoglycemia.
  • Use of systemic glucocorticoids (stable dose daily inhaled corticosteroid allowed)
  • Chronic viral hepatitis C; subjects with a history of hepatitis C successfully treated can enroll >12 months after sustained virologic response
  • Alcohol or substance use disorder in the past year as defined by DSM-V or positive urine drug screen
  • Current pregnancy, actively seeking to become pregnant or breastfeeding
  • Any serious health or other condition which, in the opinion of the Principal Investigator or their designee, could potentially interfere with the ability of a subject to comply with the procedures and assessments of the protocol or to safely participate and complete the study

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03489109

Contacts

Contact:   Cheryl L. Chairez (301) 496-3840 chairezc@mail.nih.gov

Locations

United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

Principal Investigator: Colleen M Hadigan, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
More Information

More Information

Additional Information:

NIH Clinical Center Detailed Web Page

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT03489109   History of Changes  
Other Study ID Numbers: 180075  
  18-I-0075  
Study First Received: April 4, 2018  
Last Updated: April 17, 2020  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by National Institutes of Health Clinical Center (CC):

Fasting

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Metabolic Syndrome
Insulin Resistance
Syndrome
Weight Loss

ClinicalTrials.gov processed this data on May 24, 2020
This information is provided by ClinicalTrials.gov.